Status:
COMPLETED
Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Panic Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paro...
Eligibility Criteria
Inclusion
- Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
- Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
- Provide a written informed consent
Exclusion
- Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
- Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
- Psychopharmacologic drugs within 14 days of study day 1
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2006
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00195598
Start Date
January 1 2005
End Date
April 1 2006
Last Update
April 2 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Jundiaí, São Paulo, Brazil
2
Santo André, São Paulo, Brazil, 09290-610
3
São Paulo, São Paulo, Brazil, 04038-031
4
São Paulo, São Paulo, Brazil, 04829-000